Results 121 to 130 of about 2,599,480 (386)
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Treatment patterns and factors associated with discontinuation of monoclonal antibodies
SAGE Open MedicineBackground: Biological agents have revolutionized care in specialties such as oncology, immunology, infectious diseases, and genetic disorders, offering targeted actions on specific molecules or select immune cells. Monoclonal antibodies, known for their
Muzoon Matar Saleh Alkaabi +3 more
doaj +1 more source
ImmunobiologyMonoclonal antibodies are playing an increasingly important role in modern medicine. Human monoclonal antibodies have become a key focus in the development of monoclonal antibody therapeutics due to their safety.
Guanglei Gu +6 more
doaj +1 more source
Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses. [PDF]
, 1981 The idiotype of a mouse monoclonal anti-I-E antibody, 14-4-4S, has been studied using a heterologous anti-idiotypic reagent. This antibody recognizes Ia.
Bluestone, JA +3 more
core
Insights into neutralization of animal viruses gained from study of influenza virus [PDF]
, 1991 It has long been known that the binding of antibodies to viruses can result in a loss of infectivity, or neutralization, but little is understood of the mechanism or mechanisms of this process.
Colonno +17 more
core +2 more sources
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Journal of Lipid Research, 2002 We established five monoclonal antibodies that reacted with human LCAT and recognized different epitopes on LCAT. These are mouse anti-human LCAT monoclonal antibodies designated 36487, 36454, 36442, 36405, and 36486, which react with the peptides ...
Kiichiro Kobori +5 more
doaj +1 more source
Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]
, 1992 The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Flieger, Dimitri +10 more
core +1 more source
Therapeutic Monoclonal Antibodies
The Keio Journal of Medicine, 2011 Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs ...
openaire +4 more sources
The E3 ubiquitin ligase, RNF219, suppresses CNOT6L expression to exhibit antiproliferative activity
FEBS Open Bio, EarlyView.We identified RNF219 as a CCR4‐NOT complex‐interacting E3 ubiquitin ligase that targets the CCR4‐NOT subunit CNOT6L for ubiquitination. RNF219 directly binds to the DUF3819 domain of CNOT1 through its putative α‐helix spanning amino acids 521–542. Our findings also suggest that antiproliferative activity of RNF219 is at least partially mediated by ...
Shou Soeda +9 more
wiley +1 more source